drugset / Trial / NCT02305901

The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers

NCT02305901

Phase 1 Completed 18 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To assess the influence of BI 187004 on pharmacokinetics of CYP2C8 and CYP2B6 probe drugs repaglinide and bupropion as a means of predicting drug-drug interactions.

Timeline

Start
2014-12
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 187004 Small molecule
Subject Bupropion Small molecule
Subject Repaglinide Small molecule

Indications

No indication recorded.